Evaluation of efficacy and safety of anti-fungal drug for treatment of oral candidiasis

Evaluation of efficacy and safety of anti-fungal drug for treatment of oral candidiasis - Anti-fungal drug therapy for oral candidiasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002231

Enrollment

244

Registered

2009-07-27

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral candidiasis

Interventions

Itrizole internal use group: To take 20ml (200mg as itoraconazole) of Itorizole oral solution 1% before breakfast for 14 days. Itrizole gargling group: Gargle 10ml (100mg as itraconazole) of Itorizo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patient with oral candidiasis (2) Age of 20 to 75 years old (3) Male and female

Exclusion criteria

Exclusion criteria: (1) Patient who has history for another anti-fungal drug usage within a week. (2) Patient who has severe liver dysfunction (3) Patient with pregnancy or brest-feeding (4) Patient who hope pregnancy during trial duration (5) Patient who is evaluated with unfitness by the physician (6) Patient who is taking contraindicational drug

Design outcomes

Primary

Measure	Time frame
There is no significant differences of therapeutic effect between gargling group and internal use group. The adverse effect of gargling group is lower than that of internal use.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026